Vornorexant and lemborexant, two sleep medicines, cut reported time to fall asleep by about 10–15 minutes versus a dummy pill after two weeks. A review combined seven studies involving 2,805 adults with ongoing trouble sleeping. Their average age was about 55, and 69% were women. Researchers compared daily doses of 5 or 10 milligrams of each medicine. They also looked at Sleep Efficiency: the share of time in bed spent asleep. At two weeks, lemborexant cut time to fall asleep by about 12 minutes at 5 milligrams. At 10 milligrams, the drop was about 15 minutes. Vornorexant cut that time by about 11 and 10 minutes, respectively. These were average improvements beyond those seen with a dummy pill. They do not prove one medicine works better than the other. Both medicines improved reported Sleep Efficiency at both doses after one and two weeks. The source did not give the size of those gains. Vornorexant at 10 milligrams did not clearly reduce time awake after first falling asleep. Better sleep and side effects both matter. Both lemborexant doses were linked to more sleepiness and more people reporting side effects. Neither vornorexant dose showed a clear difference from the dummy pill on safety measures. That does not mean it has no risks. For BioSocial members, these results offer context rather than a target number. The sleep measures came from people's reports, not wearable readings. Comparing your own Sleep Efficiency trends with notes on daytime alertness can give community discussions more context. These short-term results cannot tell us how benefits hold up over months. What changes in your Sleep Efficiency have lined up with feeling more rested—or sleepier—during the day?